Dealing in securities
Johannesburg, Friday, 25 September 2020. In compliance with paragraphs 3.63 to 3.74 of the JSE Listings Requirements, the following information is disclosed:
- VESTING IN SHARE APPRECIATION RIGHTS AND SALE OF ORDINARY SHARES BY PRESCRIBED OFFICER
The following transactions are disclosed in relation to SARS:
| Name of director: | VP Tobias (Prescribed Officer) |
| Nature of transaction: | The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2014: | 17 November 2019 |
| Number of 2014 SARS vested to date: | 15 618 |
| 2014 SARS issue value per share: | R18.41 |
| 1-day Volume Weighted Average price of shares | R96.0163 |
| Nature of transaction: | On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: | 12 623 |
| Date of sale: | 18 September 2020 |
| Selling price per share: | R94.0390 |
| Day highest sale price: | R95.8200 |
| Day lowest sale price: | R91.5100 |
| Proceeds for total on market sale: | R1 187 054.30 |
| Class of Securities: | Ordinary Shares |
|
Nature and extent of prescribed officer’s interest: |
Direct beneficial |
Prior clearance was obtained in respect of the above dealings by the prescribed officer.
For more details contact:
Marian van der Walt
Senior Group Executive: Enterprise Risk and Investor Relations
+27(0)82 888 1242 (mobile)
Max Manoeli
Senior Investor Relations Coordinator
+27(0)82 759 1775 (mobile)
Johannesburg, South Africa
25 September 2020
Sponsor:
J.P. Morgan Equities South Africa Proprietary Limited